Tech Stock News
Thursday, March 23, 2023
Sorrento Therapeutics Inc (NASDAQ: SRNE) announced that the company received a clearance from FDA (The U.S Food and Drug Administration) to proceed with the phase 2 trial of Non-Opioid Product Candidate Resiniferatoxin (RTX) for moderate to severe (OAK) osteoarthritis of the knee pain. Phase 1 provides efficacy: As per the […]
Sorrento Therapeutics Inc (NASDAQ: SRNE) today broadcasted the conclusion of registration for its Phase 2 scientific pilot of Abivertinib in hospitalized COVID-19 patients in Brazil. This learning conclusion trails the lately finished registration of the U.S. Phase 2 scientific pilot. Statistics from the study is estimated to be accessible for […]